Abstract

The dawn of the new millennium heralded the era of novel biological agents in the treatment of advanced cancers. Foremost have been the anti-angiogenic compounds led by the confirmation of bevacizumab as a key component of front-line therapy in advanced colorectal cancer in 2004. Ovarian cancer is one of only a few solid tumours that responds to single-agent anti-VEGF therapy. VEGF inhibitors are also active when administered in combination with chemotherapy in a variety of settings including chemonaive patients and in combination with metronomic chemotherapy for recurrent disease. This review focuses on the emergent data of new anti-angiogenic therapies in advanced ovarian cancer. We describe the developments to date, ongoing pivotal studies and critically appraise the role of novel anti-angiogenics in the treatment of ovarian cancer.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.